about
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discoveredThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionThe role of maintenance therapy in acute promyelocytic leukemia in first complete remissionFlow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemiaRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerAcute promyelocytic leukemia: where did we start, where are we now, and the futureThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesDual effect of oxidative stress on leukemia cancer induction and treatmentHow I treat pediatric acute myeloid leukemiaHow animal models of leukaemias have already benefited patientsChildhood acute myeloid leukaemiaMechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cellsNano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoA review in the treatment of oncologic emergencies.Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsTreatment advances have not improved the early death rate in acute promyelocytic leukemia.Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia.A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsClinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centreHigh-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARADevelopment and validation of a 3-Plex RT-qPCR assay for the simultaneous detection and quantitation of the three PML-RARa fusion transcripts in acute promyelocytic leukemiaATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraNewly diagnosed acute promyelocytic leukemiaMutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic TrioxideAll-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemiaTerminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.Development of therapeutic agents for older patients with acute myelogenous leukemia.High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic SyndromeTreatment of acute promyelocytic leukemia for older patients.Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.Recurrent Arterial Thrombosis as a Presenting Feature of a Variant M3-Acute Promyelocytic Leukemia.Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cellsAtypical features in a patient with acute promyelocytic leukaemia: a potential diagnostic pitfall.Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.Comparison of laboratory characteristics between acute promyelocytic leukemia and other subtypes of acute myeloid leukemia with disseminated intravascular coagulation.
P2860
Q23671266-8B7D0D90-2CA7-4A76-ADB4-E76DA078493CQ24200224-96F9EDE0-54D8-44A2-8F97-A15CA9571BA2Q24203970-C10E87CD-4AA3-4D3A-8D24-80494D270546Q24604850-6B1EF393-9383-4FB7-AFAE-1590477D195BQ26800202-F2398343-47C5-4DDA-B1C4-3D3260A41932Q26830385-58CD101D-2BA0-42B4-AE3B-BA829ED67448Q26853348-2F73EF18-FA6B-438D-B1A2-021CD8F8D499Q26866544-330EFEFD-3E47-470B-83B3-E24C4B9F3F7AQ26992280-E05BE569-45C9-4EA1-B2F5-FC4B9B5A115DQ26997702-D556FDAF-E139-4209-906C-57FCAA05F6A6Q27005960-B7254A11-A822-4DE9-9152-02EC69F59057Q27852289-A08FBE37-E173-4593-9D94-5331D3806D8DQ28393380-EC1D6E36-D9A7-4A7A-A256-59CF47CA5D63Q28488457-331ADC49-DF04-4EC4-8536-9B9950705E0DQ30252082-339E3629-AFF2-4FCE-96FB-1D1E85F9715EQ33555287-0A9C1957-F1CC-4DDC-B92A-F1282E055AC2Q34223654-C352A68B-A611-44C6-B7D2-48A7B09BF0C7Q34254302-42D54B28-BFA2-44E2-8043-339A653EACCBQ34287738-B90A17A6-5425-4FD6-AD9E-8B3276B130A0Q34305899-7ED45FD6-59FE-41A1-830F-563653BFF4CAQ34953881-95B12603-57AE-408D-91B4-3C5E7847640CQ35062053-BCBD63A6-EAEB-4978-9166-D08EDE703B1BQ35225262-C1785B82-D55A-41A2-93DB-92C4681F0085Q35623353-BC6124FE-D42E-446C-BB16-5E6079FA8ACAQ35640734-BA66B0B6-6E78-4F1E-B23A-6E3677261FC6Q35640773-381A8336-4D4D-4BE3-898D-C9E8BB126E67Q35949253-C8133ABB-9F03-4437-BE16-3AD33B2BB44CQ36070904-3838A165-8FBF-434D-B5B1-555FC79B3890Q36189756-F228FD60-594E-48E2-A05C-A96B3E27FB33Q36272117-C54D1577-6F7B-450A-B865-50C841E1A5ACQ36410157-1A96EB58-6274-4010-B4EC-2182596C1E1CQ36424315-14B2ABF9-2FF5-42E5-BEC1-3E51995E9800Q36612579-DF222B0B-37F7-4005-A29F-4A32B92647A7Q36672084-C0E301E1-07BF-4F62-9D8D-2B153F2B53CFQ37011134-E97E8984-24BA-4B84-A2DA-9790FCDF0EE2Q37055535-85D56A23-D9E6-48E6-9144-80F139C2F5ACQ37194931-317E99BA-A335-43B3-BD15-2D51D3AB6B86Q37223764-F76F6361-1763-4793-B5C3-B44774F901FBQ37397791-9448D1E5-338D-4A1C-AE10-E018D3805746Q37488633-3145CF81-2209-4F29-A14E-CB18E7A17062
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
How I treat acute promyelocytic leukemia.
@ast
How I treat acute promyelocytic leukemia.
@en
type
label
How I treat acute promyelocytic leukemia.
@ast
How I treat acute promyelocytic leukemia.
@en
prefLabel
How I treat acute promyelocytic leukemia.
@ast
How I treat acute promyelocytic leukemia.
@en
P1433
P1476
How I treat acute promyelocytic leukemia.
@en
P2093
Jessica K Altman
P304
P356
10.1182/BLOOD-2009-07-216457
P407
P577
2009-12-01T00:00:00Z